AI assistant
Lasa Supergenerics Limited Earnings Release 2021
61953_rns_2021-06-01_1d7557b4-f9db-4838-b5c9-16b1827aa67c.pdf
Earnings Release
Open in viewerOpens in your device viewer
Ref. No.: LASA/SE/21-22/11
Tuesday, June 1st 2021
| To, | To, |
|---|---|
| Corporate Services Department | Corporate Services Department |
| BSE Limited | National Stock Exchange of India Limited |
| Phiroze Jeejeebhoy Towers, | "Exchange Plaza", Plot No. C/1, |
| Dalal Street, | G Block Bandra-Kurla Complex, |
| Mumbai –400 001. | Bandra (E), Mumbai –400 051. |
| BSE CODE –540702 | NSE CODE: LASA |
Dear Sir/Madam,
Subject: Media Release
Attached is the copy of Press Release titled "LASA SUPERGENERICS ANNOUNCES ROBUST PAT AT 22.80CRS, UP 521% YOY, with Recommendation of Dividend" issued by the company.
You are requested to take the same on your record.
Yours Sincerely FOR LASA SUPERGENERICS LIMITED
NIDHI KULSHRESHTHA COMPANY SECRETARY AND COMPLIANCE OFFICER
Media Release
LASA SUPERGENERICS ANNOUNCES ROBUST PAT AT 22.80CRS, UP 521% YOY, with Recommendation of Dividend
Mumbai,1 thJune 2021: Lasa Supergenerics Limited, a vertically integrated group spanning the entire animal and human healthcare value chain has announced its financial results for the fourth quarter and Financial Year ended March 31 st , 2021.
FY21 performance overview compared with FY20
- Revenue from operations ups by 20.98% YOY
- Revenues from operations stood at Rs. 202.38 crore as compared to 167.27 crore
- EBITDA of Rs. 47.28 crore; y-o-y growth of 56.63%
- o EBITDA margins at 23.36%
- PAT stood at Rs. 22.80 crore as compared to a profit of Rs. 3.66 crore in FY20 ups by 521% YOY
- EPS for FY21 stood at Rs. 5.60, as compared to Rs. 1.26 for FY20
For fourth quarter ended March 31st 2021
Revenues from operations for the fourth quarter ended March 31st, 2021(Q4FY21) at Rs. 39.10 Crore.
The Company reported Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) of Rs. 9.08 crore in Q4FY21, as against Rs 12.75crore in Q3FY21. The Company's EBITDA margin stood at 23.24%
The Company reported PAT of Rs. 3.82crore for Q4FY21.The Company's PAT margin stood at 9.76%
Earnings per share (EPS) for the quarter ended Q4FY21 stood at Rs0.93
For financial year ended 31stMarch 2021
Total Income for the FY21 ended 31st March 2021 at Rs.202.38crore.
The Company reported Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) of Rs. 47.28 crore in FY21, as against Rs 30.18crore in FY20; up 56.63%. The Company's EBITDA margin improved from 18.04% in FY20 to 23.36% in FY21.
The Company reported a healthy increase in its PAT to Rs. 22.80 crore for FY21, as compared to a profit of Rs. 3.67 crore in the last fiscal. The Company's FY21 PAT margin stood at a robust 11.26%, as against 2.19% in FY20.
The finance cost drastically reduced from 8.10 Crore in FY20 to Rs 1.96 crore in FY21 and ultimately making it NIL in Q4FY21.
The Current Ratio improved from 1.00 in FY20 to 1.59 in FY21.
Commenting on the performance, Dr. Omkar Herlekar, Chairman– Lasa Supergenerics Limited, said,
"The Company under the right leadership and skilled teams turned net positive to post a PAT in last fiscal and now dividend paying company with a robust growth in top via a vis bottom line.
As I always say let our action speaks, results are in line with our commitments of 20% CAGR in topline, what we committed we delivered, we foresee further growth in our numbers if compared to existing.
None the less as you see we have initiated dividend payments from this fiscal which we aim to continue with a decent growth every quarter or a fiscal depending upon the market scenarios"
About Lasa Supergenerics Limited (www.lasalabs.com/; BSE: 540702; NSE: LASA)
Incorporated in 2011, Lasa Supergenerics Limited is a globally well trusted brand with high quality products, accepted by large companies across the globe. Our Company is the pioneer and amongst the leading players in the manufacturing of Veterinary APIs, with a well-established brand known for its high-quality products amongst various customers. The Company has its unit with state of art manufacturing facilities located at Mahad & Chiplun, Maharashtra with a total installed capacity of 4,300 MT. The Company has over 25% of APIs exported to counties like Australia, Bangladesh, Middle East, China, Turkey, Egypt, Jordan, Korea, Pakistan etc.
For more information contact:
Mr. Hitesh Wadhwani LasaSupergenerics Ltd. Tel: 7798888147 E-mail: [email protected]
DISCLAIMER:
Certain statements that are made in the Press Release may be forward-looking statements. Such forwardlooking statements are subject to certain risks and uncertainties like significant changes in economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Lasa Supergenerics Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forwardlooking statements to reflect subsequent events or circumstances.